Science-led peptides. Uncompromising standards.

A stabilised C-terminal fragment of human growth hormone. Research indicates selective interaction with adipose tissue lipolytic pathways, without systemic IGF-1 elevation.

• ≥98% Purity
• Lyophilised
• 5 mg / vial

A proprietary neuropeptide blend supporting the neurological pathways associated with sustained focus and cognitive resilience under physiological stress conditions.

• ≥98% Purity
• Lyophilised
• 80 mg / vial

A collagen-stimulating formulation combining GHK-Cu with pro-collagen signals. Studied for extracellular matrix remodelling, skin elasticity, and wound resolution.

• ≥98% Purity
• Lyophilised
• 70 mg / vial

A naturally occurring copper-binding tripeptide with three decades of peer-reviewed research. Implicated in wound healing, anti-inflammatory signalling, and hair follicle activation.

• ≥99% Purity
• Lyophilised
• 50 mg / vial

A synthetic GHRH analogue with a documented clinical profile. Studied for visceral adiposity reduction and IGF-1 stimulation, with a well-characterised pharmacokinetic profile.

• ≥98% Purity
• Lyophilised
• 10 mg / vial

A synthetic heptapeptide analogue of the endogenous immunomodulator tuftsin. Studied for anxiolytic-like modulation of GABAergic and serotonergic signalling, alongside effects on BDNF expression and immune pathway regulation.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, this heptapeptide is studied for upregulation of BDNF and NGF expression, neuroprotective signalling, and the pathways associated with sustained cognitive focus.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Known in research as elamipretide, this mitochondria-targeted tetrapeptide selectively binds cardiolipin on the inner mitochondrial membrane. Research indicates support for bioenergetic efficiency and cristae stability under conditions of oxidative stress.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Structurally related to GHK-Cu, this copper-binding tripeptide (Ala-His-Lys) is studied for hair follicle stimulation, dermal vascularisation, and connective tissue support within cosmetic and dermatological research.

• ≥98% Purity
• Lyophilised
• 50mg/vial

A selective growth hormone secretagogue and ghrelin-receptor agonist. Research indicates stimulation of pulsatile growth hormone release with minimal impact on cortisol and prolactin, offering a well-characterised secretory profile.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Engineered as a long-acting amylin analogue for extended receptor engagement. Studied for its influence on satiety signalling, gastric emptying, and the metabolic pathways associated with weight management.

• ≥98% Purity
• Lyophilised
• 10mgg/vial

Pairing the gastric pentadecapeptide BPC-157 with the thymosin beta-4 fragment TB-500. Investigated for complementary roles in angiogenesis, cellular migration, and the coordinated processes underlying tissue repair.

• ≥98% Purity
• Lyophilised
• 20mg/vial

A synthetic fragment of the actin-regulating protein thymosin beta-4. Studied for its involvement in cell migration, angiogenesis, and the coordinated cellular processes underlying tissue repair and remodelling.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Classed as an oestrogen-related receptor (ERR) agonist and characterised as an exercise mimetic. Researched for its activation of mitochondrial biogenesis and the oxidative metabolic pathways associated with endurance capacity.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Known in research as bremelanotide, this synthetic melanocortin peptide acts as an MC4R agonist. Studied for its activity within central nervous system pathways implicated in arousal and libido regulation.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Encoded within the mitochondrial genome, MOTS-c is a mitochondrial-derived peptide studied for AMPK activation and its role in metabolic homeostasis, glucose regulation, and insulin sensitivity.

• ≥98% Purity
• Lyophilised
• 10mg/vial

A modified C-terminal fragment of human growth hormone (residues 177-191). Research indicates selective lipolytic activity within adipose tissue, without IGF-1 elevation or measurable effects on glucose metabolism.

• ≥98% Purity
• Lyophilised
• 5mg/vial

A proprietary regenerative peptide blend combining cytoprotective and angiogenic signals. Studied for accelerated tissue repair and characterised by involvement in the pathways associated with structural recovery and remodelling.

• ≥98% Purity
• Lyophilised
• 20mg/vial

A C-terminal tripeptide fragment of alpha-MSH. Research indicates modulation of anti-inflammatory signalling pathways, with particular focus on gut and mucosal barrier integrity under inflammatory challenge.

• ≥98% Purity
• Lyophilised
• 10mg/vial

A stable gastric pentadecapeptide derived from a human protective protein found in gastric juice. Studied for angiogenic signalling, gastrointestinal lining integrity, and tendon and ligament repair pathways.

• ≥98% Purity
• Lyophilised
• 5mg/vial

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal peptide epithalamin. Implicated in telomerase modulation, circadian regulation, and the cellular pathways associated with longevity and biological ageing research.

• ≥98% Purity
• Lyophilised
• 10mg/vial

A dual GIP and GLP-1 receptor agonist with a documented clinical profile. Studied for glycaemic control and visceral adiposity reduction through complementary incretin signalling mechanisms.

• ≥98% Purity
• Lyophilised
• 10mg/vial

Engineered as a single-molecule triple agonist of the GLP-1, GIP and glucagon receptors. Research indicates convergent action across metabolic pathways implicated in energy expenditure, glycaemic regulation, and weight management.

• ≥98% Purity
• Lyophilised
• 10mg/vial